scholarly journals Risk of de novo cancer after premenopausal bilateral oophorectomy

2021 ◽  
Author(s):  
Nan Huo ◽  
Carin Y. Smith ◽  
Liliana Gazzuola Rocca ◽  
Walter A. Rocca ◽  
Michelle M. Mielke
Keyword(s):  
De Novo ◽  
Bilateral Oophorectomy ◽  
De Novo Cancer

Cancer Development and Mortality Differences in Patients with Glomerulonephritis after Renal Biopsy: A Single Center Retrospective Cohort Study

2020 ◽  
Author(s):  
Hyunjin Ryu ◽  
Kipyo Kim ◽  
Jiwon Ryu ◽  
Hyung-Eun Son ◽  
Ji-Young Ryu ◽  
...  
Keyword(s):  
Cohort Study ◽  
Renal Biopsy ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Clinical Characteristics ◽  
De Novo ◽  
Hazard Ratio ◽  
Cancer Development ◽  
De Novo Cancer

Abstract Background: The association between glomerulonephritis (GN) and cancer has been well known for decades. However, studies evaluating long-term de novo cancer development in patients with GN are limited. This study aimed to evaluate the incidence of cancer development among patients with renal biopsy-proven GN during post-biopsy follow-up and the differences in outcomes according to cancer occurrence. Methods: We conducted a retrospective cohort study of adult patients who underwent renal biopsy at Seoul National Bundang Hospital between 2003 and 2017. After excluding 671 patients who are inappropriate for the analysis, 929 patients were included in the analysis. Data on baseline clinical characteristics, renal biopsy results, and types and doses of immunosuppressant agents used during follow-up were collected from electronic medical records. The incidence of cancer was censored on the date when the first cancer was diagnosed. We evaluated rates of mortality and end-stage renal disease (ESRD) development during follow-up. Results: During a mean follow-up period of 52.4 (range: 1.0–166.7) months, 49 subjects (5.3%) developed de novo cancer. A comparison of clinical characteristics between subjects who did and did not develop cancer revealed that cancer patients were older and had higher comorbidities and immunosuppressant use. Overall, patients with GN had an elevated standardized incidence ratio (SIR) of 7.17 (95% confidence interval (CI): 5.3–9.51) relative to the general population. In particular, the SIR was significantly higher in GNs such as membranous nephropathy (MN), IgA nephropathy, lupus nephritis, and focal segmental glomerulosclerosis. Multivariable Cox proportional hazard model adjusted for confounding variables revealed that patients with a pathologic diagnosis of MN had an increased risk of cancer development, with a hazard ratio of 2.6 [95% CI: 1.32–5.30]. Patients with MN who developed cancer had a significantly higher risk of mortality (hazard ratio: 5.95; 95% CI: 1.36–26.09, P=0.018) than those without cancer, but there was a non-significant difference in ESRD development. Conclusions: Patients with GN without concurrent cancer, particularly those with MN, have significantly higher risks of cancer development and subsequent mortality and should remain aware of the potential development of malignancy during follow-up.

scholarly journals Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease

2019 ◽  
Vol 15 (7) ◽  
pp. e616-e627 ◽  
Author(s):  
Michael J. Hassett ◽  
Matthew Banegas ◽  
Hajime Uno ◽  
Shicheng Weng ◽  
Angel M. Cronin ◽  
...  
Keyword(s):  
Advanced Cancer ◽  
Cancer Diagnosis ◽  
De Novo ◽  
Stage Iv ◽  
Absolute Difference ◽  
Medicare Data ◽  
Stage Iv Disease ◽  
De Novo Cancer ◽  
Payment Models ◽  
Diagnosis Age

PURPOSE: Spending for patients with advanced cancer is substantial. Past efforts to characterize this spending usually have not included patients with recurrence (who may differ from those with de novo stage IV disease) or described which services drive spending. METHODS: Using SEER-Medicare data from 2008 to 2013, we identified patients with breast, colorectal, and lung cancer with either de novo stage IV or recurrent advanced cancer. Mean spending/patient/month (2012 US dollars) was estimated from 12 months before to 11 months after diagnosis for all services and by the type of service. We describe the absolute difference in mean monthly spending for de novo versus recurrent patients, and we estimate differences after controlling for type of advanced cancer, year of diagnosis, age, sex, comorbidity, and other factors. RESULTS: We identified 54,982 patients with advanced cancer. Before diagnosis, mean monthly spending was higher for recurrent patients (absolute difference: breast, $1,412; colorectal, $3,002; lung, $2,805; all P < .001), whereas after the diagnosis, it was higher for de novo patients (absolute difference: breast, $2,443; colorectal, $4,844; lung, $2,356; all P < .001). Spending differences were driven by inpatient, physician, and hospice services. Across the 2-year period around the advanced cancer diagnosis, adjusted mean monthly spending was higher for de novo versus recurrent patients (spending ratio: breast, 2.39 [95% CI, 2.05 to 2.77]; colorectal, 2.64 [95% CI, 2.31 to 3.01]; lung, 1.46 [95% CI, 1.30 to 1.65]). CONCLUSION: Spending for de novo cancer was greater than spending for recurrent advanced cancer. Understanding the patterns and drivers of spending is necessary to design alternative payment models and to improve value.

scholarly journals Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: An association with C2 monitoring and recipient age

2010 ◽  
Vol 16 (7) ◽  
pp. 837-846 ◽  
Author(s):  
Angela S. W. Tjon ◽  
Jerome Sint Nicolaas ◽  
Jaap Kwekkeboom ◽  
Robert A. de Man ◽  
Geert Kazemier ◽  
...  
Keyword(s):  
De Novo ◽  
Liver Graft ◽  
Recipient Age ◽  
C2 Monitoring ◽  
De Novo Cancer

scholarly journals Depressed-Type Colonic Lesions and “De Novo” Cancer in Familial Adenomatous Polyposis: A Colonoscopist’s Viewpoint

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Shin-ei Kudo ◽  
Yuusaku Sugihara ◽  
Hiroyuki Kida ◽  
Fumio Ishida ◽  
Hideyuki Miyachi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Familial Adenomatous Polyposis ◽  
De Novo ◽  
Early Stage ◽  
Colorectal Cancers ◽  
Adenomatous Polyposis ◽  
Depressed Type ◽  
Polyposis Syndrome ◽  
De Novo Cancer ◽  
Almost All

Familial adenomatous polyposis (FAP) is the most common inherited polyposis syndrome. Almost all patients with FAP will develop colorectal cancer if their FAP is not identified and treated at an early stage. Although there are many reports about polypoid lesions and colorectal cancers in FAP patients, little information is available concerning depressed lesions in FAP patients. Several reports suggested that depressed-type lesions are characteristic of FAP and important in the light of their rapid growth and high malignancy. Here, we describe the occurrence of depressed-type lesions in FAP patients treated at our institution. Between April 2001 and March 2010, eight of 18 FAP patients had colorectal cancers. Depressed-type colorectal cancer was found in three patients. It should be kept in mind that depressed-type lesions occur even in FAP.

A single-institution survey of de novo secondary malignancies in patients occurring after orthotropic liver transplantation.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 297-297
Author(s):  
Quentin Gillebert ◽  
Mohamed Bouattour ◽  
Francois Durand ◽  
Claire Francoz ◽  
Valerie Paradis ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplantation ◽  
De Novo ◽  
Secondary Malignancy ◽  
Prior History ◽  
Lung Cancers ◽  
History Of ◽  
Independent Risk Factors ◽  
De Novo Cancer ◽  
Tumor Types

297 Background: We aim to evaluate in our institution the incidence of de novo malignancies following orthotopic liver transplantation (OLT) and their impact the prognosis of patients (pts). Methods: Pts treated with OLT from August 1991 To March 2009 were considered in this analysis. All pts data had been prospectively recorded in the database of French “Bio-medecine Agence”. Pts were considered for this analysis only if they survived at least 3-months after. Occurrence of de novo malignancies we analyzed and additional data (including immunosuppressive profile, type of cancer, potential independent risk factors of cancers, prognosis and the influence of immunosuppression protocols or risk factors on occurrence of cancers) were collected in patients who developed secondary cancers. Results: A total of 833 patients who underwent OLT were considered for this analysis. With a median follow-up of 7.9 years, 72 pts developed 92 de novo malignancies. The overall incidence of cancers in our population was 10.4% occurring with a median time of 6.1 years following OLT. Sixteen pts developed 2 different types of cancer and 2 pts had more than 3 tumor types. Before 12/1998, immunosuppression was primarily based on cyclosporine, steroids and/or azathiopirine, and since 01/1999 was switched to tacrolimus. Incidence of cancers regarding these two periods is summarized in the table. Before 1998, only 3 pts (17.6%) with secondary cancer had prior history of alcoholism and/or smoking compared to 27 pts (50%) after 1999. Thirty one deaths were observed and the median overall survival (OS) after the time of diagnosis of secondary malignancy was 5.62 years. Conclusions: The risk of de novo cancer after OLT is similar to reported series. History of smoking and alcohol use, increase the incidence of de novo malignancies especially head and neck and lung cancers however, immunosuppression type may not interfere with this risk. [Table: see text]

De Novo Cancer After Orthotopic Liver Transplantation

1998 ◽  
Vol 30 (4) ◽  
pp. 1484-1485 ◽  
Author(s):  
V Peyrègne ◽  
C Ducerf ◽  
M Adham ◽  
E.de la Roche ◽  
N Berthoux ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Orthotopic Liver Transplantation ◽  
De Novo ◽  
De Novo Cancer

scholarly journals Early colorectal cancer from “de novo” carcinogenesis with submucosal invasion: a case report and review of the literature

2021 ◽  
Author(s):  
hua jiang ◽  
chiyi he
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
De Novo ◽  
Normal Mucosa ◽  
Submucosal Invasion ◽  
Screening Colonoscopy ◽  
Early Colorectal Cancer ◽  
Lesion Type ◽  
De Novo Cancer ◽  
Low Incidence

Abstract Background: Colorectal cancer (CRC) mostly develops through the traditional “adenoma-carcinoma sequence”, however there is a rare “de novo” carcinogenic pathway in which cancer originates from normal mucosa. Here, we report a case of early CRC caused by “de novo” carcinogenesis with submucosal invasion and conduct a literature review of this special type of CRC.Case presentation: A 66-year-old man underwent a screening colonoscopy that revealed a polyp-like lesion (type 0-IIa+IIc in the Paris classification) approximately 0.5 cm in diameter in the descending colon. The patient underwent endoscopic submucosal dissection (ESD); postoperatively, he was pathologically diagnosed with moderately differentiated adenocarcinoma without an adenomatous component from the “de novo” carcinogenic pathway, accompanied by submucosal invasion to a depth of 600 μm. There was no venous or lymphatic permeation, and the margins were negative. A year later, follow-up examinations did not reveal tumour recurrence.Conclusions: Early “de novo” cancer has a low incidence and a low discovery rate through endoscopy. In this case report, we provide informative details about the presentation of such cancers under endoscopy and further support for the aggressive malignant potential of early “de novo” cancer. The development of advanced CRC can be effectively prevented, and the prognosis of these patients can be improved with active early treatment.

Sign in / Sign up

Export Citation Format

Share Document